Adult toy company Minna Life is accepting pre-orders on Kickstarter for its kGoal pelvic trainer device and app, which it claims is the world's first smart kegel trainer.
Even though the biotech IPO market has been sputtering under the weight of a wave of new offerings and some heightened skepticism of what's being put in front of investors these days, two more biotechs have laid out plans to raise a total of some $150 million.
Researchers at Tohoku University in Japan have come up with a stretchable and durable electrode-hydrogel that could open the door for the development of new generations of wearable and implantable devices.
The top R&D spenders in med tech invested between 6% and 12% of their devices' sales back into med tech R&D. From dental products to diagnostics to laboratory equipment, cardiology, imaging and orthopedics, the list reflects the variety of businesses in the med tech arena.
A drug-eluting patch developed by researchers at Nanyang Technological University in Singapore could offer a solution for patients with overgrown scar tissue.
Harvard University researchers have developed a system for releasing high doses of drugs in short bursts using ultrasound and self-healing hydrogel. Future therapy could therefore be highly customized and locally delivered at specific times, as opposed to the dominant sustained release paradigm.
Bristol-Myers Squibb claimed bragging rights to the first batch of Phase III data on an immuno-oncology drug that clearly demonstrated an improvement over a standard therapy for overall survival.
InVivo Therapeutics announced June 19 that it is terminating its preclinical hydrogel drug delivery program as the company focuses on its investigational devices for spinal cord injury, the Neuro-Spinal Scaffold and the Neuro-Spinal Scaffold Plus Stem Cells.
Pharma companies have taken some heat for their R&D productivity levels as of late, but drug developers and investors may recently have seen some of their faith restored.
Four more drug developers are angling to make Wall Street debuts, lining up to raise a combined $269 million as the market for biotech IPOs has shown renewed signs of life after a tepid spring.